Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth's SelectMDx Liquid Biopsy Test for Prostate Cancer

MDxHealth, in conjunction with DDL Diagnostic Laboratory, has launched SelectMDx patient testing in the Netherlands, with plans to expand the offering to other European countries in early 2016. The test is made up of novel biomarkers discovered by Jack Schalakan and uses a non-invasive "liquid biopsy" method to identify patients at low risk for prostate cancer using urine samples. In clinical studies, SelectMDx has been shown to outperform PCA3, improving the information available to urologists seeking to further reduce unnecessary invasive biopsy procedures, said MDxHealth in a statement.

The Scan

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.